Atlas Trials

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Clinical trial NCT01458249 · COMPLETED

Trial details

NCT number
NCT01458249
Sponsor
Eisai Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Soft Tissue Sarcoma
Start date
2011-11-01
Primary completion
2014-11-01
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.